Literature DB >> 6690749

Should an elevated human chorionic gonadotropin titer alter therapy for seminoma?

D A Swartz, D E Johnson, D H Hussey.   

Abstract

We reviewed the clinical courses of 55 patients with pure seminoma of the testis to determine the influence of elevated levels of beta-human chorionic gonadotropin on prognosis. Of 44 patients with stage I and 11 with stage IIA seminomas 42 and 36 per cent, respectively, had elevated gonadotropin levels after orchiectomy and before radiotherapy. At followup, ranging from 12 to 64 months, 54 patients (98 per cent) were free of disease. We concluded that an elevated gonadotropin level after orchiectomy is not a significant prognostic indicator and that these patients should be treated with standard radiotherapy techniques.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690749     DOI: 10.1016/s0022-5347(17)50204-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Treatment of stage I seminoma: should beta-HCG positive seminoma be treated aggressively?

Authors:  K Suzuki; H Nakazato; K Kurokawa; T Suzuki; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  Seminoma testis with elevated serum beta-HCG--a category of germ-cell cancer between seminoma and nonseminoma.

Authors:  K P Dieckmann; W Düe; H W Bauer
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

3.  Testicular neoplasms: seminoma.

Authors:  E K Reddy; M Burke; S Giri; L Krishnan; L Gemer; R Evans; W K Mebust; J Wiegel
Journal:  J Natl Med Assoc       Date:  1990-09       Impact factor: 1.798

4.  HLA-antigen distribution in seminoma, HCG-positive seminoma and non-seminomatous tumours of the testis.

Authors:  C Kratzik; P Aiginger; R Kuzmits; J Spona; M Kirnbauer; A Seiser; W R Mayr
Journal:  Urol Res       Date:  1989

5.  Postoperative reduction of serum beta-HCG in testicular seminoma.

Authors:  S Sakashita; T Demura; T Gotoh; A Maru; T Koyanagi
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.